We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Clear Labs

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and a... read more Featured Products: More products

Download Mobile App





Groundbreaking Solution Enables Enhanced Screening and Genomic Surveillance of SARS-CoV-2 and its Mutations

By LabMedica International staff writers
Posted on 17 Sep 2021
Print article
Image: Clear Dx platform (Photo courtesy of Clear Labs)
Image: Clear Dx platform (Photo courtesy of Clear Labs)
The first-ever turn-key solution for whole genome sequencing (WGS) of COVID-19 is expected to help hospitals, reference labs, public health organizations and epidemiologists more easily identify and trace all strains of SARS-CoV-2.

Clear Labs (San Carlos, CA, USA), provider of the only fully-automated next-generation sequencing (NGS) platform for turnkey diagnostics, has launched Clear Dx WGS, the first automated WGS solution that determines the complete RNA sequence of the SARS-CoV-2 genome in less than 24-hours, a fraction of time, compared with traditional manual WGS workflows, requiring only minutes of hands-on time. The Clear Dx platform is powered by NGS, robotics and cloud-based analytics. As a result, Clear Dx WGS can more easily determine the nature of virus transmission by differentiating virus strains (including flagging super-spreader events), and monitoring mutations, which can lead to variants.

By delivering rapid sequencing of the whole genome, the Clear Dx platform provides fully-automated library preparation and management, including cDNA synthesis, amplification of targets, indexing, and nucleic acid clean-up. It also provides simplified WGS workflow with ~30 minutes hands-on time (i.e. 1-2 human touch points vs. several dozen touch points with existing manual WGS workflows). Additionally, the platform offers faster results - from days to less than 24 hours; improved consistency in sample processing and accuracy of results; and lower labor costs and greater lab productivity.

“This is a pivotal time for our understanding and management of the ongoing COVID-19 pandemic, and better, more accurate intel is critical,” said Jeff Field, Chief Commercial Officer at Clear Labs. “Our platform can identify different subtypes of the SARS-CoV-2 virus based on its genomic fingerprint. We recognize that it’s no longer enough to confirm cases, it’s about understanding the mutations and evolution of the virus, so the virus can be traced and understood. Ultimately, this leads to timely decisions which can be made to keep people safe. With our unique approach that democratizes genomics applications, Clear Dx WGS can quickly identify new subtypes, mutations, and variants to gain real-time clarity into virus transmission, so it's actionable.”

“In addition to WGS, the platform also features the Clear Dx SARS-CoV-2 Diagnostic Assay (EUA approved) which allows labs to perform diagnostic screening and genomic surveillance simultaneously,” added Field. “For the same price of a traditional PCR screening test, our fully-automated targeted NGS assay delivers same-day results and a comprehensive look into the virus - by differentiating positives into genomic subtypes and flagging clinically-relevant lineages or mutations, such as B.1.1.7, B.1.351, L452R, and D614G. Given the evolution of SARS-CoV-2, it's imperative that the market starts to adopt and implement NGS-based testing solutions to ensure that new strains such as B.1.1.7 are not being missed by conventional testing methods.”



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.